In Vitro and In Vivo Antihyperglycemic Effects of New Metabiotics from Boletus edulis

Anca Zanfirescu; Ionela Avram; Florentina Gatea; Răzvan Roșca; Emanuel Vamanu

doi:10.3390/life14010068

In Vitro and In Vivo Antihyperglycemic Effects of New Metabiotics from Boletus edulis

Life (Basel). 2023 Dec 30;14(1):68. doi: 10.3390/life14010068.

Authors

Anca Zanfirescu¹, Ionela Avram², Florentina Gatea³, Răzvan Roșca⁴, Emanuel Vamanu⁵

Affiliations

¹ Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.
² Department of Genetics, University of Bucharest, 36-46 Bd. M. Kogalniceanu, 5th District, 050107 Bucharest, Romania.
³ Centre of Bioanalysis, National Institute for Biological Sciences, 296 Spl. Independentei, 060031 Bucharest, Romania.
⁴ Anoom Laboratories SRL, 18th Resita Str., ap. 58, 4th District, 024023 Bucharest, Romania.
⁵ Faculty of Biotechnology, University of Agricultural Sciences and Veterinary Medicine, 011464 Bucharest, Romania.

Abstract

The increasing incidence of diabetes has prompted the need for new treatment strategies, including natural products that reduce glycemia values. This work examined the in vitro and in vivo antihyperglycemic effects of new metabiotics derived from Boletus edulis extracts. The metabiotics were obtained from 100% B. edulis, and two other products, CARDIO and GLYCEMIC, from Anoom Laboratories SRL, which contain other microbial species related to B. edulis. Our in vitro investigations (simulations of the microbiota of patients with type 2 diabetes (T2D)) demonstrated that B. edulis extracts modulate the microbiota, normalizing its pattern. The effects were further tested in vivo, employing a mouse model of T2D. The tested extracts decreased glycemia values compared to the control and modulated the microbiota. The metabiotics had positive effects on T2D in vitro and in vivo, suggesting their potential to alleviate diabetes-associated microbiota dysbiosis.

Keywords: modulation process; mouse; pattern; simulation.

Grants and funding

This research was partially supported through the Competitiveness Operational Program, Axis 1, Action 1.2.3, SMIS no 105535 (FITOCOMP), subcontract 975/20.04.2022, and from the private funds of Anoom Laboratories SRL.